STEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss
NCT06571383 on ClinicalTrials.gov · last registry update 2026-06-02
An unusually large phase 4: 500 participants, more than double the 72 typical for the stage. Due to report 15 November 2028, alongside 16 other tracked readouts that quarter. Primary outcome, as filed: Maintenance of Body Mass Index (BMI) below obesity threshold. Sponsors move these dates routinely; any movement since this site started watching is listed below. It has been running since 17 September 2024 — 2 years so far. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- P4
- Drug
- semaglutideRybelsus, Wegovy, Ozempic
- Sponsor
- Novo Nordisk A/S
- Sponsor type
- Industry
- Enrollment
- 500
- Started
- 2024-09-17
- Primary completion
- 2028-11-15 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Maintenance of Body Mass Index (BMI) below obesity threshold
Conditions studied
Obesity
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.